Literature DB >> 33719239

[Treatment of peri-implant refracture after intramedullary nail fixation for intertrochanteric fractures].

Lin Teng1, Yongchuan Xiao1, Gang Zhong2.   

Abstract

OBJECTIVE: To investigate the occurrence, treatment, and effectiveness of peri-implant refracture after intramedullary nail fixation for intertrochanteric fractures.
METHODS: The clinical data of 16 patients with peri-implant refracture after intramedullary nail fixation for intertrochanteric fractures who met the inclusion criteria between April 2014 and November 2019 were retrospectively analyzed. There were 7 males and 9 females with an average age of 78.4 years (range, 65-93 years). The 14 cases of initial intertrochanteric fractures were classified according to the classification of AO/Orthopaedic Trauma Association (AO/OTA): 5 cases of type A1, 7 cases of type A2, and 2 cases of type A3; the other 2 cases were intertrochanteric combined with subtrochanteric fractures (Seinsheimer type Ⅴ). According to the classification of peri-implant refracture which was proposed by Chan et al., there were 10 cases of type 1 (6 cases of type 1A, 3 cases of type 1B, 1 case of type 1C) and 6 cases of type 2 (4 cases of type 2A and 2 cases of type 2B). The average interval between refracture and initial surgery was 14.6 months (range, 1-52 months). The incidence of peri-implant refracture in short nail group (the length of intramedullary nail used in initial surgery≤240 mm) was 1.92% (11/573), while the incidence of long nail group (the length of intramedullary nail used in initial surgery≥340 mm) was 1.66% (5/301), showing no significant difference between the two groups ( χ 2=0.073, P=0.786). The peri-implant refractures were revised with extended intramedullary nail (5 cases) or fixed with additional limited invasive stabilization system (11 cases).
RESULTS: The average operation time was 115.8 minutes (range, 78-168 minutes) and the average intraoperative blood loss was 283.1 mL (range, 120-500 mL). One patient died of myocardial infarction at 3 months after operation, and the other 15 patients were followed up 9-46 months (mean, 16.8 months). The peri-implant refractures healed at 14-20 weeks (mean, 16.4 weeks) after operation. There was no complications such as incision infection, nonunion, internal fixator loosening and rupture, screw cutting-out, and the second refracture during the follow-up. At last follow-up, all injured limbs regained walking function, and the Hospital for Special Surgery (HSS) score was 56-92 (mean, 80.2). The results were classified as excellent in 2 cases, good in 10, fair in 2, and poor in 1, with the excellent and good rate of 80%.
CONCLUSION: Stress concentration at the tip of initial intramedullary nail and distal interlocking screw aera is the main cause of peri-implant refracture after intramedullary nail fixation for intertrochanteric fractures. Revision with extended intramedullary nail or fixation with limited invasive stabilization system according to the length of initial intramedullary nail and the type of refracture can get satisfactory effectiveness.

Entities:  

Keywords:  Intertrochanteric fracture; intramedullary nail; refracture; stress concentration

Mesh:

Year:  2021        PMID: 33719239      PMCID: PMC8171760          DOI: 10.7507/1002-1892.202010011

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  26 in total

Review 1.  Occurrence of secondary fracture around intramedullary nails used for trochanteric hip fractures: a systematic review of 13,568 patients.

Authors:  Rory Norris; Dhritiman Bhattacharjee; Martyn J Parker
Journal:  Injury       Date:  2011-12-03       Impact factor: 2.586

2.  Fixation of intertrochanteric fractures of the femur. A randomised prospective comparison of the gamma nail and the dynamic hip screw.

Authors:  S H Bridle; A D Patel; M Bircher; P T Calvert
Journal:  J Bone Joint Surg Br       Date:  1991-03

3.  Short Versus Long Intramedullary Nails in the Treatment of Pertrochanteric Hip Fractures: Incidence of Ipsilateral Fractures and Costs Associated With Each Implant.

Authors:  Eric Lindvall; Samia Ghaffar; Armen Martirosian; Lisa Husak
Journal:  J Orthop Trauma       Date:  2016-03       Impact factor: 2.512

Review 4.  Fractures of the femur after hip replacement.

Authors:  C P Duncan; B A Masri
Journal:  Instr Course Lect       Date:  1995

5.  Nail or plate fixation of intertrochanteric hip fractures: changing pattern of practice. A review of the American Board of Orthopaedic Surgery Database.

Authors:  Jeffrey O Anglen; James N Weinstein
Journal:  J Bone Joint Surg Am       Date:  2008-04       Impact factor: 5.284

6.  Short versus long cephalomedullary nails for the treatment of intertrochanteric hip fractures in patients older than 65 years.

Authors:  Conor Kleweno; Jordan Morgan; James Redshaw; Mitchel Harris; Edward Rodriguez; David Zurakowski; Mark Vrahas; Paul Appleton
Journal:  J Orthop Trauma       Date:  2014-07       Impact factor: 2.512

7.  Peri-implant femoral fractures: The risk is more than three times higher within PFN compared with DHS.

Authors:  F Müller; M Galler; M Zellner; C Bäuml; A Marzouk; B Füchtmeier
Journal:  Injury       Date:  2016-05-07       Impact factor: 2.586

8.  Results of a compression pin alongwith trochanteric external fixation in management of high risk elderly intertrochanteric fractures.

Authors:  Aydın Arslan; Ali Utkan; Tuba Tulay Koca
Journal:  Indian J Orthop       Date:  2016 Nov-Dec       Impact factor: 1.251

Review 9.  Intramedullary versus extramedullary internal fixation for unstable intertrochanteric fracture, a meta-analysis.

Authors:  Xi Yu; Hong Wang; Xin Duan; Ming Liu; Zhou Xiang
Journal:  Acta Orthop Traumatol Turc       Date:  2018-03-27       Impact factor: 1.511

Review 10.  Long versus short cephalomedullary nail for trochanteric femur fractures (OTA 31-A1, A2 and A3): a systematic review.

Authors:  John Dunn; Nicholas Kusnezov; Julia Bader; Brian R Waterman; Justin Orr; Philip J Belmont
Journal:  J Orthop Traumatol       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.